Unity Biotechnology (NASDAQ:UBX) Releases Quarterly Earnings Results

Unity Biotechnology (NASDAQ:UBX) released its quarterly earnings results on Monday. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.02, Zacks reports.

Unity Biotechnology Trading Up 1.7 %

Shares of Unity Biotechnology stock traded up $0.02 during trading hours on Thursday, reaching $1.17. 5,064 shares of the company’s stock were exchanged, compared to its average volume of 63,103. The firm has a market capitalization of $19.71 million, a price-to-earnings ratio of -0.88 and a beta of 0.83. Unity Biotechnology has a 52-week low of $1.11 and a 52-week high of $2.26. The company has a fifty day moving average of $1.43 and a 200-day moving average of $1.47.

Analyst Ratings Changes

UBX has been the topic of a number of analyst reports. Rodman & Renshaw began coverage on Unity Biotechnology in a report on Thursday, August 22nd. They set a “buy” rating and a $8.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Unity Biotechnology in a research report on Thursday, August 8th.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.